News

IO Biotech to Present at Upcoming Healthcare Conferences

IO Biotech to Present at Upcoming Healthcare Conferences

IO Biotech to Participate in Upcoming Investor Conferences

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company focused on developing innovative immune-modulating therapeutic cancer vaccines using the T-win platform, has announced that its senior management team will be participating in several upcoming investor conferences. These events will provide valuable insights into the company's current projects and future prospects.

Conference Details

At the Morgan Stanley 22nd Annual Global Healthcare Conference, Dr. Mai-Britt Zocca, the CEO of IO Biotech, will take part in a fireside chat on September 4, 2024, at 5:35 pm ET. This conference presents a significant opportunity for IO Biotech to engage with potential investors and share updates on the ongoing developments of their therapeutic offerings.

Participation in the H.C. Wainwright Conference

Following that, Amy Sullivan, the CFO of IO Biotech, will present the company’s strategic initiatives at the H.C. Wainwright 26th Annual Global Investment Conference on September 9, 2024, at 10:30 am ET. This presentation aims to highlight the progress of IO Biotech's pipeline and its innovative approaches to cancer treatment.

Webcast Access

For those interested, a live webcast of these presentations will be available on IO Biotech's official website, allowing remote engagement with the content. After the events, the recordings will be accessible for about 90 days, enabling broader audience participation.

About IO102-IO103

IO102-IO103 is an experimental cancer vaccine designed to activate the immune system against both tumor cells and the immunosuppressive cells that hinder effective immune responses within the tumor microenvironment (TME). This pioneering therapy seeks to enhance T cell activation against indoleamine 2,3-dioxygenase (IDO) positive and programmed death-ligand 1 (PD-L1) positive cells, which are crucial targets in cancer therapy.

Clinical Trials and Collaborations

The clinical trials for IO102-IO103 are currently in critical phases. The company is conducting a Phase 3 trial (NCT05155254) that compares the vaccine in combination with pembrolizumab to pembrolizumab alone in patients with advanced melanoma. Additionally, a Phase 2 basket trial (NCT05077709) is underway to assess its effectiveness as a first-line treatment for various solid tumors, along with another Phase 2 study (NCT05280314) focusing on neo-adjuvant/adjuvant treatments. These studies are sponsored by IO Biotech in collaboration with Merck, which is providing pembrolizumab for the trials.

About IO Biotech

IO Biotech is an innovative clinical-stage biopharmaceutical company dedicated to developing immune-modulating cancer therapies. Their T-win platform offers a novel approach to cancer vaccine technology, leveraging the body’s immune response to target tumor-supportive cells. IO Biotech is advancing its lead candidate, IO102-IO103, through clinical trials while also assessing additional candidates at the preclinical stage.

Based on encouraging data from Phase 1/2 trials for metastatic melanoma, IO102-IO103 has been granted breakthrough therapy designation by the US Food and Drug Administration, enhancing its potential impact in the oncology field. IO Biotech operates globally, with its headquarters in Copenhagen and a significant presence in New York.

Contact Information

Investors
Maryann Cimino, Director of Investor Relations
IO Biotech, Inc.
617-710-7305
Email: mci@iobiotech.com

Media
Julie Funesti
Salutem
917-498-1967
Email: Julie.Funesti@salutemcomms.com

Frequently Asked Questions

What is the focus of IO Biotech?

IO Biotech specializes in developing immune-modulating therapeutic cancer vaccines.

When will IO Biotech present at investor conferences?

IO Biotech will participate in the Morgan Stanley Conference on September 4, 2024, and the H.C. Wainwright Conference on September 9, 2024.

How can I access the presentations from IO Biotech?

The webcast of the presentations will be available on IO Biotech's website for 90 days following the events.

What is IO102-IO103?

IO102-IO103 is an investigational therapeutic cancer vaccine targeting tumor cells and immune-suppressive cells in the tumor microenvironment.

Who are IO Biotech's collaborators for clinical trials?

IO Biotech conducts its clinical trials in collaboration with Merck, which supplies pembrolizumab for ongoing studies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

ACME's AI Innovation Shakes Up Filmmaking Scene

Updated Category News Views 87

The Game-Changer in Virtual Production You ever hear about the Grey Box™ phenomenon? Sounds like a sci-fi gizmo, right? Turns out, it's the real deal and ACME Media's been riding this revolutionary wave straight to the top of the film industry ladder. Their approach with this AI-driven gizmo isn't just about cutting-edge tech wizardry—it's reimagining how we shoot...

Continue Reading
Choosing Expert European Auto Repair: Key Insights

Updated Category News Views 127

The Perks of Specialist Knowledge Ever get the feeling your local auto shop doesn't always cut it when your sleek BMW or classy Mercedes needs a tweak? You're not alone. Specifically, for those driving around Alpharetta, European vehicles demand not just routine check-ups but specialist hands. Much like how you wouldn't hand your luxury timepiece to the shop down the...

Continue Reading
Chime Joins S&P MidCap 400 Amid Merger Jostle

Updated Category News Views 194

Index Shake-Up: Who's In, Who's Out? Hold onto your hats, folks—big changes are coming to the S&P MidCap 400! Chime Financial Inc. is crashing the party, taking a seat at the table, as NorthWestern Energy Group gets the boot. Now, if that doesn’t grab your attention, I don’t know what will. You've got to appreciate the chaos and opportunities that come with a roster...

Continue Reading
Perpetua Reports Q3 2026 Results, Progress on Project

Updated Category News Views 81

A Steady Climb for Perpetua Resources It's like watching a boxer steadily climb the ranks, waiting for the big title fight. That's the scene with Perpetua Resources (NASDAQ:PPTA) as their Q3 2026 financial results hit the wires. No confetti cannons this time, just solid, gritty steps towards a promising future. Q3 Financial Results: A Prudent Path The financials for...

Continue Reading
Matthew Callstrom Named CEO: Mayo Clinic's Next Era

Updated Category News Views 215

Leadership Change at Mayo Clinic: A Turning Point The Mayo Clinic, a titan in healthcare lands, is on the cusp of a major leadership switch-up. As the trustees hand the reins to Dr. Matthew R. Callstrom, they're banking on a rich blend of experience and visionary thinking to steer their ship. We're looking at what this change might spell for Mayo's storied mission. Who is...

Continue Reading
Surprising Week on Wall Street: Chips Drive Gains

Updated Category News Views 141

A Wild Week in Wall Street Well, folks, what a week it’s been on Wall Street. The indexes danced the cha-cha, making gains despite closing Friday on a lower note. Despite the retreat, we've got ourselves a week where the major indexes closed higher than the previous Friday. It's not the usual story, but who ever thought stocks played by the rules? The Nasdaq Composite...

Continue Reading
Backdoor Reference Checks: A Hiring Minefield?

Updated Category News Views 181

What's Really Happening with Job References? Every job seeker has been there, right? You're all set, resume polished to a shine, references lined up like a choir ready to sing your praises, and then bam—you hear that employers are contacting folks you never listed. A new report from Zety highlights this eyebrow-raising trend, and it's got us all questioning the value...

Continue Reading
Foreigner to Rock Irvine with Night Ranger in 2027

Updated Category News Views 85

Irvine Set for a Rock Revival Talk about a blast from the past! On March 27, 2027, two titans of the rock world, Foreigner and Night Ranger, are set to ignite Irvine like it's the glory days of arena rock all over again. Hosted at the Great Park Live, this show isn't just a concert—it's a full-scale invasion of rock's golden age right into Southern California's heart....

Continue Reading
LA Fitness ELEVATE Opens at RITHM: A New Era Dawns

Updated Category News Views 66

Elevating Fitness at RITHM: A New Era Has Begun RD Management just dropped a new ace in Tampa Bay’s hand—LA Fitness ELEVATE at the RITHM at Uptown. They lit up the scene with this 30,000-square-foot beast of a gym, and I’ll tell you, it’s not your standard run-of-the-mill joint. When you toss twelve-and-a-half million bucks into a pot, you're aiming to lure folks...

Continue Reading
Breakthrough T1D Pushes Global T1D Awareness Forward

Updated Category News Views 54

Shining a Light on T1D with Global Efforts In a world where a change in lifestyle can happen at the drop of a hat, Breakthrough T1D is making waves by expanding their global "See T1D" campaign in honor of World Diabetes Day. This isn't your run-of-the-mill awareness push—this is about propelling an understanding of what life truly entails for those living with type 1...

Continue Reading

Top 5 Most Recently Viewed Articles

LLCP Promotions: A Positive Spin or a Prelude to Trouble?

Updated Category News Views 211

Levine Leichtman Capital Partners (LLCP) just gave its Finance and Administration team a shake-up with promotions announced on February 17, 2026. Sure, the firm hails from Los Angeles—where they like to keep things sunny—but these moves might be less about shining futures and more about staving off trouble. Who’s Climbing the LLCP Ladder? Key Players Promoted...

Continue Reading
Understanding Novo Nordisk's Market Sentiment and Trends

Updated Category News Views 187

Novo Nordisk's Current Short Interest Overview Novo Nordisk's short percent of float has decreased substantially, reflecting a 7.89% drop since its last report. The company has disclosed that there are currently 23.58 million shares sold short. This figure corresponds to around 0.7% of all the shares that are available for public trading. Given the trading activity,...

Continue Reading
LG Innotek Launches Innovative Digital Key to Transform Driving

Updated Category News Views 226

Revolutionizing Vehicle Access with Innovative Technology LG Innotek has introduced an exciting new product, the 'Next-generation Digital Key Solution'. This innovative technology connects smartphones to vehicles, allowing users to lock and unlock doors and start engines seamlessly through wireless communication. The digital key’s unique design eliminates the risk of...

Continue Reading
Exciting Opportunities: Auction Details for Office Properties

Updated Category News Views 318

Exciting Opportunities: Auction Details for Office Properties Hilco Real Estate Sales has recently announced an upcoming auction featuring two prominent office buildings designed to capture interest from investors and developers alike. Set in highly visible locations, these properties are prime candidates for a range of investment opportunities. Auction Announcement The...

Continue Reading
Grease Monkey and SpeeDee Oil Change Celebrate Franchise Success

Updated Category News Views 243

Grease Monkey and SpeeDee Oil Change Shine in Franchise Rankings Grease Monkey and SpeeDee Oil Change have recently made headlines after securing their spots in the coveted Franchise Times Top 400 list. This recognition showcases their growth and resilience in the automotive service sector, highlighting the commitment to providing excellent service to their customers. A...

Continue Reading